Does Dupixent Help Nasal Polyps?
Yes, Dupixent (dupilumab) is FDA-approved to treat chronic rhinosinusitis with nasal polyps (CRSwNP) in adults whose condition remains inadequately controlled despite intranasal corticosteroids.[1] Clinical trials showed it reduces nasal congestion, polyp size, and sinus opacification while improving sense of smell and quality of life.
How Does Dupixent Work for Nasal Polyps?
Dupixent blocks signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two cytokines driving type 2 inflammation that causes nasal polyps, mucus production, and tissue swelling in CRSwNP.[1][2] Administered as a subcutaneous injection every two weeks after an initial dose, it targets the underlying inflammation rather than just symptoms.
What Do Clinical Trials Show?
In the phase 3 SINUS-24 and SINUS-52 trials, patients on Dupixent plus standard therapy saw their nasal polyp score drop by 1.89 to 2.06 points (on a 0-8 scale) at week 24, compared to 0.17-0.87 points with placebo plus therapy.[1] Congestion scores improved by about 0.87-1.17 points versus 0.24-0.32 for placebo. Sense of smell (UPSIT score) rose by 13.1-18.0 points on Dupixent, versus 2.2-6.1 on placebo. Benefits persisted up to 52 weeks.
Who Qualifies for Dupixent Treatment?
It's approved for adults 18+ with CRSwNP not responding to nasal corticosteroids, often those who've had or need repeated sinus surgeries.[1] Not for acute sinusitis or polyps without chronic rhinosinusitis. Doctors assess via endoscopy, CT scans, and symptom history before starting.
What Side Effects Do Patients Report?
Common reactions include injection-site reactions (10-18%), conjunctivitis (2-10%), and joint pain (1-5%). Serious risks like hypersensitivity or eosinophilia occur rarely (<1%). Herpes infections rose slightly in trials. Eye issues like keratitis prompted monitoring recommendations.[1][2] Long-term data shows most tolerate it well, but some discontinue due to eye symptoms.
How Does It Compare to Surgery or Steroids?
Dupixent reduces polyp recurrence post-surgery and delays need for it—52-week surgery rates were 8.4-12.7% versus 27.8-36.0% on placebo.[1] Unlike oral steroids, which carry risks like osteoporosis with prolonged use, Dupixent offers sustained control without systemic steroids. It's not a cure but shrinks polyps more effectively than intranasal steroids alone.
When Does Insurance Cover Dupixent for Polyps?
Most U.S. plans cover it after prior authorization proving failed intranasal therapy, with list price around $3,400 monthly (wholesale).[3] Patient assistance programs from Sanofi/Regeneron reduce costs for eligible uninsured or underinsured. Biosimilars are not yet available.
[1] FDA Label: Dupixent (dupilumab) prescribing information, updated 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761055s050lbl.pdf
[2] New England Journal of Medicine: Dupilumab in CRSwNP (SINUS trials), 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2103408
[3] Drugs.com: Dupixent pricing and coverage. https://www.drugs.com/price-guide/dupixent